Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data from 9222 Chronic Heart Failure Patients of the ESC-HFA-EORP Heart Failure Long-Term Registry
Patrick Rossignol(Inserm), Frank Ruschitzka(Kantonsspital St. Gallen), Gianluigi Savarese(Karolinska Institutet), María G. Crespo‐Leiro(Complexo Hospitalario Universitario A Coruña), Gerasimos Filippatos(National and Kapodistrian University of Athens), Theresa A. McDonagh, Andrew J.S. Coats(The Heart Research Institute), Mitja Lainščak, Ana Sahuquillo(Fundación Hospital Manacor), Maria Penco(University of Messina), Giuseppe Rosano(St George's Hospital), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Massimo Piepoli(University of Milan), Aldo P. Maggioni(Health Care Foundation), Lars H. Lund(Karolinska University Hospital), Petar M. Seferovic(University of Belgrade), Stefan D. Anker(Bayer (Germany)), Cécile Laroche(European Society of Cardiology)
Cited by 148
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
2016 European Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2016|6.5k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k